TABLE 3.
Pancreatic NET (N = 31) |
Small Intestine NET (N = 64) |
||
---|---|---|---|
CD45RO | Intra-tumoral, n (%) | ||
Low | 11 (36) | 31 (53) | |
High | 20 (65) | 28 (48) | |
Extra-tumoral, n (%) | |||
Low | 6 (26) | 25 (81) | |
High | 17 (74) | 6 (19) | |
CD3 | Intra-tumoral, n (%) | ||
Low | 16 (52) | 32 (54) | |
High | 15 (48) | 27 (45) | |
Extra-tumoral, n (%) | |||
Low | 10 (50) | 26 (94) | |
High | 10 (50) | 1 (4) | |
CD8 | Intra-tumoral, n (%) | ||
Low | 21 (68) | 51 (86) | |
High | 10 (32) | 8 (14) | |
Extra-tumoral, n (%) | |||
Low | 11 (50) | 28 (96) | |
High | 11 (50) | 1 (4) | |
FOXP3 | Intra-tumoral, n (%) | ||
Low | 30 (97) | 59 (100) | |
High | 1 (3) | 0 (0) | |
Extra-tumoral, n (%) | |||
Low | 22 (100) | 30 (100) | |
High | 0 (0) | 0 (0) |
Infiltrates were assessed based on T-cell marker expression and in the intra and extra-tumoral compartments separately. Low and high level infiltrates were defined as infiltrates with scores of 0–1 or 2–3, respectively, as defined in the Methods section.